At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
VTP-38543 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle-Controlled Ascending Multiple Dose and Clinical Proof-Of-Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating VTP-38543, Vehicle with Transcutol®P, and 1 other intervention for Dermatitis, Atopic. Completed, enrolled 104 participants across 12 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult male and female participants with mild to moderate atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedJan 2016
Primary CompletionSep 2016
TodayJul 2026
First PostedJan 14, 2016
Enrollment StartDec 15, 2015
Primary CompletionSep 9, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.5 years ago
Interventions
VTP-38543drug
VTP-38543 topical cream
Vehicle with Transcutol®Pother
Vehicle matching VTP-38543 cream with Transcutol®P
Vehicle without Transcutol®Pother
Vehicle matching VTP-38543 cream without Transcutol®P